Journal article
Clinical and dosimetric factors associated with acute rectal toxicity in patients treated with Cs-131 brachytherapy for prostate cancer
Brachytherapy, v 9(4), pp 328-334
01 Oct 2010
PMID: 20116341
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
PURPOSE: Cs-131 has been recently introduced for use in prostate brachytherapy. We wished to identify clinical and dosimetric factors associated with acute bowel/rectal toxicity in patients treated with Cs-131.
METHODS AND MATERIALS: Patients treated with Cs-131 prostate brachytherapy at the University of Pittsburgh were asked to complete expanded prostate cancer index composite surveys preoperatively and at 2-4 weeks and 3 months postimplant. We identified patients who experienced acute and persistent acute bowel toxicity to determine if any factors could correlate with either situation.
RESULTS: One hundred six patients were treated with Cs-131 from September 2006 to May 2008. Thirty-eight percent of patients met our criteria for patient-appreciated acute bowel symptoms. On multivariate analysis, the volume of rectum receiving 50% of the prescribed dose (R-V-50, 4.1 vs. 2.6 cc, p = 0.01), R-V-75 (1.3 vs. 0.62 cc, p = 0.01), the percentage of the prescribed dose received by 1 cc of the rectum (R-D-1cc; 75% vs. 64%, p = 0.02), and R-D-2cc (63% vs. 54%, p = 0.003) were found to be factors associated with a greater risk of severe acute bowel toxicity. At 3-month followup, 28% of patients had persistent acute bowel toxicity. On multivariate analysis, no factors were identified that correlated with persistent acute bowel toxicity.
CONCLUSIONS: This study identifies R-V-50, R-V-75, R-D-1cc, and R-D-2cc as factors associated with patient-appreciated acute rectal toxicity. We are performing dosimetric analysis to determine the optimal distance for the posterior needles from the prostate rectal interface to decrease rectal dose while still maintaining adequate coverage of prostate. (C) 2010 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
Metrics
Details
- Title
- Clinical and dosimetric factors associated with acute rectal toxicity in patients treated with Cs-131 brachytherapy for prostate cancer
- Creators
- Abhay S. Gokhale - UPMC Hillman Cancer CenterSushil Beriwal - University of PittsburghRyan P. Smith - University of PittsburghXiang Li - University of PittsburghRonald Benoit - University of Pittsburgh
- Publication Details
- Brachytherapy, v 9(4), pp 328-334
- Publisher
- Elsevier
- Number of pages
- 7
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:000283282900009
- Scopus ID
- 2-s2.0-77957331327
- Other Identifier
- 991021897271704721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Oncology
- Radiology, Nuclear Medicine & Medical Imaging